Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in ...
| Ticker |
Sentiment |
Impact |
|
REGN
|
Neutral
|
4 %
|
|
META
|
Neutral
|
1 %
|
|
SNY
|
Neutral
|
19 %
|
